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The new pandemic pathogen, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) or 
Coronavirus disease 2019 (COVID-19), causes a wide 
range of symptoms that differ from mild cold‐like 
symptoms to pneumonia and death. This virus has 
been an international public health emergency since 
December, 2019 due to its high infectious rate. Beyond 
the pathogenesis of COVID-19, viral co-infections play 
a vital role in the occurrence and development of this 
pandemic by increasing the difficulties of diagnosis, 
treatment and even the disease symptoms and 
mortality. Regarding clinical presentation, 
transmission and coincidence this disease is very 
similar to Middle East respiratory syndrome (MERS), 
severe acute respiratory syndrome (SARS) and 
seasonal influenza which makes it difficult to 
accurately detect [1-3]. 
The COVID-19 detection and diagnostic methods 
are mainly divided into two groups, a laboratory-based 
(such as serological tests, and real-time reverse-
transcriptase polymerase chain reaction (RT-PCR)) 
and lung computed tomography (CT) scan or chest 
radiography. Accuracy of these methods related to 
their sensitivity and specificity. Previous studies 
showed that only some of them had both sensitivity 
and specificity over 50% in detecting SARS-CoV-2 
infection. Therefore, the use of appropriate diagnostic 
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methods with sufficient accuracy is of particular 
importance in screening COVID-19 [4-6].  
Several reports indicate that viral interactions 
have some effect on the course of infectious diseases. 
Therefore, high co-infection rate might be due to the 
overlap between the emergence of COVID-19 and 
other respiratory viruses. This overlap emphasizes the 
importance of the COVID-19 screening methods, 
regardless of other positive results for other viruses in 
the initial trials [7].  
Although co-infection with dual respiratory 
viruses is uncommon in adults, but there were cases 
have been reported. Previous study showed that 
influenza A virus was one of the common viral 
pathogens causing co-infection among patients with 
COVID-19 which may have caused initial false-
negative results of RT-PCR for SARS-CoV-2 [8]. In a 
case report, co-infection of metapneumovirus and 
SARS-CoV-2 has been investigated [9]. Huang et al. 
reported a unique case of influenza B virus co-infection 
with SARS-CoV-2 in Taiwan [10]. Other viruses that 
can cause co-infection include: coronavirus, 
rhinovirus/enterovirus, respiratory syncytial virus 
(RSV), parainfluenza [11-13]. Therefore, it is necessary 
to limit the risk of secondary infections by other viruses 
that can cause false-negative results for SARS-CoV-2 
on screening methods and increase the risk of 
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mortality rate in COVID-19 patients. Recognition of 
possible viruses causing co-infection among COVID-
19 patients helps clinicians to choose appropriate 
screening method, proper management and 
therapeutic [7, 14].  
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